A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care
Targeted anti-CCP testing in primary care may aid earlier identification of people at risk of RA, prompting specialist referral to rheumatology for earlier diagnosis and initiation of disease-modifying therapy.
Authors
- E. Hensor (ORCID: https://orcid.org/0000-0002-5245-4755)
- Paul Emery (ORCID: https://orcid.org/0000-0002-7429-8482)
- Kulveer Mankia (ORCID: https://orcid.org/0000-0002-7945-6582)
- Michelle Wilson (ORCID: https://orcid.org/0000-0001-7556-1599)
- J. Nam (ORCID: https://orcid.org/0000-0003-4944-7922)
- Heidi J. Siddle (ORCID: https://orcid.org/0000-0002-6015-332X)
- Leticia Garcia‐Montoya (ORCID: https://orcid.org/0000-0002-1806-7532)
- Laurence Duquenne (ORCID: https://orcid.org/0000-0001-7631-0986)
Institutions
- University of Leeds (GB)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1093/rheumatology/keae653
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Eli Lilly and Company
- AstraZeneca
- Gilead Sciences
- National Institute for Health and Care Research
- Department of Health and Social Care
- University of Leeds
- Samsung
- Leeds Biomedical Research Centre